Atrial fibrillation

Khachatryan, A., Doobaree, I. U., Spentzouris, G., Gusto, G., Zawaneh, Y., Mughal, F., et al. (2022). Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database. Adv Ther.
van den Dries, C. J., Pajouheshnia, R., van den Ham, H. A., Souverein, P., Moons, K. G. M., Hoes, A. W., et al. (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol.
Chung, S. C., O'Brien, B., Lip, G. Y. H., Fields, K. G., Muehlschlegel, J. D., Thakur, A., et al. (2022). Prognostic model for atrial fibrillation after cardiac surgery: a UK cohort study. Clin Res Cardiol.
Wu, J., Nadarajah, R., Nakao, Y. M., Nakao, K., Wilkinson, C., Mamas, M. A., et al. (2022). Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3·4 million individuals. Lancet Reg Health Eur, 17, 100386.